Main variables;Main activity, secondary one or a tool necessary for production;Total
Companies that carry out R&D in Biotechnology;Total;1.348
Companies that carry out R&D in Biotechnology;Main;661
Companies that carry out R&D in Biotechnology;Secondary dwellings;188
Companies that carry out R&D in Biotechnology;Tool;500
%Companies according to biotechnology used: Genetic code;Total;31
%Companies according to biotechnology used: Genetic code;Main;40,3
%Companies according to biotechnology used: Genetic code;Secondary dwellings;25,2
%Companies according to biotechnology used: Genetic code;Tool;21
%Companies according to biotechnology used: Functional units;Total;38,4
%Companies according to biotechnology used: Functional units;Main;45,9
%Companies according to biotechnology used: Functional units;Secondary dwellings;37,6
%Companies according to biotechnology used: Functional units;Tool;28,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;21,7
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Main;27,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Secondary dwellings;15,9
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Tool;16,5
%Companies according to biotechnology used: Bioprocesses;Total;50,3
%Companies according to biotechnology used: Bioprocesses;Main;40,9
%Companies according to biotechnology used: Bioprocesses;Secondary dwellings;53,3
%Companies according to biotechnology used: Bioprocesses;Tool;61,7
%Companies according to biotechnology used: Sub-cellular organisms;Total;8,2
%Companies according to biotechnology used: Sub-cellular organisms;Main;12,1
%Companies according to biotechnology used: Sub-cellular organisms;Secondary dwellings;3,3
%Companies according to biotechnology used: Sub-cellular organisms;Tool;5
%Companies according to biotechnology used: Bio-computing;Total;24,1
%Companies according to biotechnology used: Bio-computing;Main;33,8
%Companies according to biotechnology used: Bio-computing;Secondary dwellings;20,2
%Companies according to biotechnology used: Bio-computing;Tool;12,9
%Companies according to biotechnology used: Nanobiotechnology;Total;11,8
%Companies according to biotechnology used: Nanobiotechnology;Main;15,9
%Companies according to biotechnology used: Nanobiotechnology;Secondary dwellings;14
%Companies according to biotechnology used: Nanobiotechnology;Tool;5,4
%Companies according to biotechnology used: Other;Total;16,4
%Companies according to biotechnology used: Other;Main;18,4
%Companies according to biotechnology used: Other;Secondary dwellings;20,3
%Companies according to biotechnology used: Other;Tool;12,3
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45,8
%Company by field(s) of ultimate application of biotechnology use: Human Health;Main;64,5
%Company by field(s) of ultimate application of biotechnology use: Human Health;Secondary dwellings;32,2
%Company by field(s) of ultimate application of biotechnology use: Human Health;Tool;26,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;15,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Main;17,2
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Secondary dwellings;14,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Tool;12,9
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;31,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Main;21,1
%Company by field(s) of ultimate application of biotechnology use: Food products;Secondary dwellings;34,9
%Company by field(s) of ultimate application of biotechnology use: Food products;Tool;44,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23,7
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Main;19,9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Secondary dwellings;32,9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Tool;25,2
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;15,5
%Company by field(s) of ultimate application of biotechnology use: Environment;Main;14,1
%Company by field(s) of ultimate application of biotechnology use: Environment;Secondary dwellings;25,4
%Company by field(s) of ultimate application of biotechnology use: Environment;Tool;13,7
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;13,4
%Company by field(s) of ultimate application of biotechnology use: Industry;Main;14,3
%Company by field(s) of ultimate application of biotechnology use: Industry;Secondary dwellings;19,1
%Company by field(s) of ultimate application of biotechnology use: Industry;Tool;10,1
Personnel in R&D in biotechnology (no. of persons);Total;15.744
Personnel in R&D in biotechnology (no. of persons);Main;8.573
Personnel in R&D in biotechnology (no. of persons);Secondary dwellings;1.786
Personnel in R&D in biotechnology (no. of persons);Tool;5.385
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total;8.380
Personnel in R&D in biotechnology (no. of persons): Research personnel;Main;5.028
Personnel in R&D in biotechnology (no. of persons): Research personnel;Secondary dwellings;952
Personnel in R&D in biotechnology (no. of persons): Research personnel;Tool;2.400
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total;7.364
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Main;3.545
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Secondary dwellings;834
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Tool;2.985
Personnel in R&D in biotechnology (no. of persons). Women;Total;8.725
Personnel in R&D in biotechnology (no. of persons). Women;Main;4.985
Personnel in R&D in biotechnology (no. of persons). Women;Secondary dwellings;952
Personnel in R&D in biotechnology (no. of persons). Women;Tool;2.788
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total;4.521
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Main;2.794
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Secondary dwellings;504
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Tool;1.223
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total;4.204
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Main;2.191
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Secondary dwellings;448
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Tool;1.565
Personnel in R&D in biotechnology (FTE);Total;11.523,2
Personnel in R&D in biotechnology (FTE);Main;6.809,8
Personnel in R&D in biotechnology (FTE);Secondary dwellings;1.008,1
Personnel in R&D in biotechnology (FTE);Tool;3.705,3
Personnel in R&D in biotechnology (FTE): Research personnel;Total;6.341,6
Personnel in R&D in biotechnology (FTE): Research personnel;Main;4.061,4
Personnel in R&D in biotechnology (FTE): Research personnel;Secondary dwellings;628,5
Personnel in R&D in biotechnology (FTE): Research personnel;Tool;1.651,7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total;5.181,6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Main;2.748,4
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Secondary dwellings;379,7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Tool;2.053,6
Personnel in R&D in biotechnology (FTE). Women;Total;6.552,7
Personnel in R&D in biotechnology (FTE). Women;Main;4.019,9
Personnel in R&D in biotechnology (FTE). Women;Secondary dwellings;569,1
Personnel in R&D in biotechnology (FTE). Women;Tool;1.963,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total;3.464,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Main;2.258,6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Secondary dwellings;349,8
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Tool;855,9
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.088,3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1.761,3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary dwellings;219,3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Tool;1.107,7
Internal expenditure on R&D (thousands of euros);Total;1.037.887
Internal expenditure on R&D (thousands of euros);Main;643.053
Internal expenditure on R&D (thousands of euros);Secondary dwellings;81.049
Internal expenditure on R&D (thousands of euros);Tool;313.785
1) By nature of the expense: Current expenses;Total;939.471
1) By nature of the expense: Current expenses;Main;569.179
1) By nature of the expense: Current expenses;Secondary dwellings;76.172
1) By nature of the expense: Current expenses;Tool;294.120
1.1) Remuneration to research personnel;Total;321.525
1.1) Remuneration to research personnel;Main;206.505
1.1) Remuneration to research personnel;Secondary dwellings;32.639
1.1) Remuneration to research personnel;Tool;82.382
1.2) Remuneration to technicians and auxiliary personnel;Total;194.656
1.2) Remuneration to technicians and auxiliary personnel;Main;105.018
1.2) Remuneration to technicians and auxiliary personnel;Secondary dwellings;12.981
1.2) Remuneration to technicians and auxiliary personnel;Tool;76.658
1.3) Other current expenses;Total;423.290
1.3) Other current expenses;Main;257.656
1.3) Other current expenses;Secondary dwellings;30.553
1.3) Other current expenses;Tool;135.081
2) By nature of the expense: Capital expenses;Total;98.416
2) By nature of the expense: Capital expenses;Main;73.874
2) By nature of the expense: Capital expenses;Secondary dwellings;4.877
2) By nature of the expense: Capital expenses;Tool;19.664
2.1) Land and buildings;Total;10.150
2.1) Land and buildings;Main;7.449
2.1) Land and buildings;Secondary dwellings;600
2.1) Land and buildings;Tool;2.102
2.2) Equipment and instruments;Total;72.538
2.2) Equipment and instruments;Main;53.214
2.2) Equipment and instruments;Secondary dwellings;3.495
2.2) Equipment and instruments;Tool;15.828
2.3) Acquisition of specific R+D software;Total;5.713
2.3) Acquisition of specific R+D software;Main;4.293
2.3) Acquisition of specific R+D software;Secondary dwellings;369
2.3) Acquisition of specific R+D software;Tool;1.051
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;10.015
2.4) Otros productos de propiedad intelectual específicos para I+D;Main;8.918
2.4) Otros productos de propiedad intelectual específicos para I+D;Secondary dwellings;413
2.4) Otros productos de propiedad intelectual específicos para I+D;Tool;684
1.1) By origin of the funds: Own funds;Total;711.037
1.1) By origin of the funds: Own funds;Main;412.945
1.1) By origin of the funds: Own funds;Secondary dwellings;55.579
1.1) By origin of the funds: Own funds;Tool;242.513
1.2) By origin of the funds: From companies;Total;121.595
1.2) By origin of the funds: From companies;Main;82.588
1.2) By origin of the funds: From companies;Secondary dwellings;8.576
1.2) By origin of the funds: From companies;Tool;30.431
1.3) By origin of the funds: Public Administration funds;Total;107.422
1.3) By origin of the funds: Public Administration funds;Main;66.483
1.3) By origin of the funds: Public Administration funds;Secondary dwellings;11.401
1.3) By origin of the funds: Public Administration funds;Tool;29.539
1.4) By origin of the funds: From Universities;Total;192
1.4) By origin of the funds: From Universities;Main;68
1.4) By origin of the funds: From Universities;Secondary dwellings;14
1.4) By origin of the funds: From Universities;Tool;111
1.5) By origin of the funds: From non profit private institutions;Total;10.756
1.5) By origin of the funds: From non profit private institutions;Main;9.444
1.5) By origin of the funds: From non profit private institutions;Secondary dwellings;0
1.5) By origin of the funds: From non profit private institutions;Tool;1.312
1.6) By origin of the funds: Foreign funds;Total;86.884
1.6) By origin of the funds: Foreign funds;Main;71.524
1.6) By origin of the funds: Foreign funds;Secondary dwellings;5.480
1.6) By origin of the funds: Foreign funds;Tool;9.880
Purchase of R&D services in biotechnology (thousands of euros);Total;145.440
Purchase of R&D services in biotechnology (thousands of euros);Main;107.282
Purchase of R&D services in biotechnology (thousands of euros);Secondary dwellings;14.145
Purchase of R&D services in biotechnology (thousands of euros);Tool;24.013
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;95.870
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Main;75.671
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Secondary dwellings;12.772
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Tool;7.428
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;49.570
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Main;31.611
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Secondary dwellings;1.374
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Tool;16.585
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;39,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Main;48,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Secondary dwellings;37,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Tool;28,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Main;11,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Secondary dwellings;15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Tool;12,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;18,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Main;20,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Secondary dwellings;20,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Tool;14,4
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Main;10,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Secondary dwellings;15,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Tool;10,7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Main;16
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Secondary dwellings;25,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Tool;11,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Main;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Secondary dwellings;21,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Tool;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Main;16,4
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Secondary dwellings;23,8
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Tool;12,7
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;40
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Main;47,3
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Secondary dwellings;42,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Tool;29,4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;53,9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Main;62,7
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Secondary dwellings;54,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Tool;41,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;21,5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Main;23,6
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Secondary dwellings;26,1
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Tool;16,9
% Companies with income of an international origin related to biotechnological activities;Total;22,2
% Companies with income of an international origin related to biotechnological activities;Main;29,9
% Companies with income of an international origin related to biotechnological activities;Secondary dwellings;15,4
% Companies with income of an international origin related to biotechnological activities;Tool;14,7
% Turnover representing income of an international origin related to biotechnological activities;Total;1,9
% Turnover representing income of an international origin related to biotechnological activities;Main;13,4
% Turnover representing income of an international origin related to biotechnological activities;Secondary dwellings;0,1
% Turnover representing income of an international origin related to biotechnological activities;Tool;1,5
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;65,5
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Main;67,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Secondary dwellings;57
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Tool;60,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;34,5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Main;32,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Secondary dwellings;43
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Tool;39,9
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;86,3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Main;82,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Secondary dwellings;91,3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Tool;96,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;12,2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;16,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary dwellings;1,2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool;0,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1,1
% Income of an international origin related with activities according to the classification: Operating source abroad;Main;0,8
% Income of an international origin related with activities according to the classification: Operating source abroad;Secondary dwellings;7,5
% Income of an international origin related with activities according to the classification: Operating source abroad;Tool;1,3
% Income of an international origin related with activities according to the classification: Other;Total;0,4
% Income of an international origin related with activities according to the classification: Other;Main;0,1
% Income of an international origin related with activities according to the classification: Other;Secondary dwellings;0
% Income of an international origin related with activities according to the classification: Other;Tool;1,3